This was a controlled, parallel-group, single-blinded, randomized pilot study carried out from March 2024 to June 2024, with chronic pain patients with the aim to evaluate the prospect of a larger ...
Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors From December 2022 to January 2025, one MRT ...
The U.S. Food and Drug Administration (FDA) is moving to speed drug development and review by launching real-time clinical trials. The move could soon mean more options for patients who need ...
In this video interview, Raj Indupuri, CEO and co-founder of eClinical Solutions, explains why organizations that build ...
Utilization management criteria influence patients’ access to specialty drugs, yet the processes used by health plans to establish these criteria are not well understood. This study examined the ...
The agency announced that it has completed the first tests of a system that allows FDA scientists to see safety and effectiveness data from patients as it is collected, turning the traditional process ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results